NCT05810142尚未招募不适用
Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- Primary efficacy endpoint: Objective Response Rate (ORR)
研究概览
简要总结
This research project is a single-center, retrospective clinical exploration study. It aims to retrospectively analyze data from 20 patients with advanced duodenal adenocarcinoma who received third-line treatment with furquinelone combined with sintilimab, in order to determine the clinical efficacy and safety of this combination therapy in advanced duodenal cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following criteria to be eligible for inclusion:
- •Age between 18 and 80 years (inclusive); Imaging findings consistent with unresectable local advanced, recurrent or metastatic duodenal adenocarcinoma; Histologically confirmed unresectable local advanced, recurrent or metastatic duodenal adenocarcinoma; ECOG performance status 0-2; At least one measurable or evaluable lesion according to RECIST v1.1; Third-line or above treatment with the combination of sintilimab and furquimatinib.
排除标准
- •Patients meeting any of the following criteria will be excluded:
- •Patients with incomplete clinical data or laboratory examination that affects statistical analysis; Patients who have had other malignant tumors in the past 5 years; Patients who have had arterial thrombotic diseases such as angina, myocardial infarction, and transient ischemic attack in the past 6 months; Patients who have received other types of anti-tumor or experimental treatment; Pregnant or lactating women; Patients with other diseases or abnormal mental status that may affect the patient's treatment; Patients who have received other types of immune therapy, anti-angiogenic drugs, or small-molecule tyrosine kinase inhibitors.
结局指标
主要结局
Primary efficacy endpoint: Objective Response Rate (ORR)
时间窗: 2 years
次要结局
未报告次要终点
研究者
chengxiaojiao
Attending physician
RenJi Hospital
相似试验
已完成
3 期
Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the EyebrowsGlabellar RhytidesFrown Lines Between the EyebrowsNCT00752050Mentor Worldwide, LLC699
Unknown
1 期
Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene SulfonateNon-small Cell Lung CancerNCT04059874First Affiliated Hospital of Zhejiang University20
进行中（未招募）
3 期
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AHemophilia ANCT06297655Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.60
Unknown
3 期
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative ResectionStage ⅠA Pancreatic CancerStage ⅠB Pancreatic CancerStage ⅡA Pancreatic CancerStage ⅡB Pancreatic CancerNCT02506842Fudan University300
已完成
3 期
A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the EyebrowsGlabellar RhytidesNCT00752258Mentor Worldwide, LLC576